Back to search results

An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Multiple Myeloma (MM) · Non-Hodgkin Lymphoma (NHL)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    Contact: Study coordinator (Jia Xu, Ph.D) · xu_jia@hust.edu.cn · +86 18274201261
Study leads

  • Heng Mei, Ph.D&M.D

    Principal Investigator

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

View source on ClinicalTrials.gov(opens in a new tab)